Vendor Intelligence Report: Mai Peptide

Executive summary

Mai Peptide is not a simple anonymous storefront, but it is not a clean retail identity either. Corporate and B2B records point behind the consumer site to a Xi'an biotechnology seller with named personnel, while domain history shows a recent brand transition: a predecessor domain appeared as TIRZ-PEPTIDE in archive captures and was later observed parked after the active storefront moved to mai-peptides.com.

Across 76 Finnrick lab tests, Mai Peptide records 58 pass and 18 fail, for an overall pass rate of 76%. The catalog is uneven: GHK-Cu and Retatrutide are the comparatively stronger reads, while Tirzepatide and Cagrilintide are poor directional choices; the Tirzepatide file includes a complete identity failure, and ratings compress under stricter grading.

The infrastructure finding is sharper than the usual shared-template noise. Mai Peptide runs on shop910, a Chinese SaaS stack marketed to gray or restricted goods merchants and advertising cloaking and AB redirect tooling. The same technical layer, CDN/R2 assets, JavaScript fingerprints, and reused testimonials connect Mai Peptide to a cluster of sister or lookalike storefronts, raising real brand-confusion and dispute-risk issues.

Our buyer read is product-specific. Mai Peptide may be a defensible only-with-safeguards option for the stronger-tested items, but it is not a good first-choice vendor for Tirzepatide or Cagrilintide, and it is a poor fit for large prepaid orders or urgent refill situations where delivery leverage matters.

Inside the full report:

• Appendix A — Finnrick Laboratory Data with per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 6 tested products
• Dated domain timeline covering TIRZ-PEPTIDE, maipeptide.com, and the active mai-peptides.com storefront
• B2B attribution evidence tying the retail brand to a Xi'an operating entity, address, email domain, and named personnel
• Shop910 infrastructure analysis, including cloaking, AB redirect, CDN paths, R2 bucket, and payment-endpoint signals
• Clone-site comparison using JavaScript hashes, shared assets, content reuse, and testimonial duplication
• Reputation, delivery, affiliate-scan, and unresolved verification leads for future monitoring

Risk assessment

• Product-specific quality inconsistency risk — high: Tirzepatide is a poor directional choice at 63.71% with 21 tests and a field-identified identity failure; Cagrilintide is also weak at 53.82%, while GHK-Cu and Retatrutide are comparatively stronger.
• Infrastructure cloaking and evasive storefront risk — high: mai-peptides.com uses shop910 infrastructure marketed for gray/restricted goods, with cloaking and AB redirect features that complicate due diligence and disputes.
• Brand-confusion and domain-hopping risk — high: The operation spans mai-peptides.com, a parked predecessor maipeptide.com, TIRZ-PEPTIDE B2B records, and clone/sister storefronts without a captured authoritative channel list.
• Marketing-claims and testimonial fabrication risk — high: Testimonials and the “20,000 customers on Alibaba” trust claim were reused across sister storefronts, and the Alibaba claim was not verified under the Mai Peptide name.
• Corporate-transparency risk — medium: Records indicate an attributable Chinese operator, Shaanxi Suke Yuancheng Biotechnology, but the consumer site does not cleanly present that ownership and uses multiple brands/domains.
• Delivery and dispute-resolution risk — medium: Trustpilot and related-domain reports include fake-tracking and non-delivery allegations, though the public sample is small.
• Opaque promotion and Discord-funnel risk — medium: The scan found Reddit promotion with owner/partner signals and no disclosed relationship, but no referral code, referral link, or paid-promotion proof.